The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
 
Keiju Aokage
Honoraria - AstraZeneca; Care Net; Chugai Pharma; Covidien; CSL Behring; International Life Sciences Institute; Japan Blood Products Organization; Johnson & Johnson; Kyowa Kirin International; Lilly Japan; medical tribune; Phase one; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Olympus Medical Systems; Sano hospital; Taiho Pharmaceutical
Research Funding - AstraZeneca; MSD
 
Yoshihisa Shimada
No Relationships to Disclose
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Wakabayashi
Honoraria - Nihon Medi-Physics
 
Miki Fukutani
No Relationships to Disclose
 
Hideki Furuya
No Relationships to Disclose
 
Kotaro Nomura
No Relationships to Disclose
 
Tomohiro Miyoshi
No Relationships to Disclose
 
Kenta Tane
No Relationships to Disclose
 
Joji Samejima
Travel, Accommodations, Expenses - B. Braun; Johnson & Johnson/Janssen; MiRXES; Olympus; Stryker; Taiho Pharmaceutical; ZIOSOFT
 
Shogo Kumagai
No Relationships to Disclose
 
Shohei Koyama
Consulting or Advisory Role - Kaken Pharmaceutical
Research Funding - Otsuka
 
Hiroyoshi Nishikawa
Stock and Other Ownership Interests - Cellian-Biclo; Sustainable Cell Therapeutics
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; MSD K.K; Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; Bayer Yakuhin; Becton Dickinson; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Debiopharm Group; Eisai; Fujifilm; Hitachi; Janssen Research & Development; Kyowa Kirin; MSD K.K.; Oncolys BioPharma; Ono Pharmaceutical; Rakuten Medical; SRL Diagnostics; Sumitomo Dainippon Pharma; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Tetsuro Taki
No Relationships to Disclose
 
Takuo Hayashi
No Relationships to Disclose
 
Jun Matsubayashi
No Relationships to Disclose
 
Genichiro Ishii
No Relationships to Disclose
 
Norihiko Ikeda
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD; Nihon Medi-Physics; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Fujifilm (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); MSD (Inst); Nihon Medi-Physics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi-Sankyo; Johnson & Johnson; Lilly Japan; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; AstraZeneca Japan; Chugai Pharma; MiRXES; MSD; Novartis
Research Funding - AstraZeneca Japan (Inst); BMG Inc (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb KK (Inst); Merck (Inst); MiRXES (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)